Poteligeo

Active Ingredient(s): Mogamulizumab-kpkc
FDA Approved: * August 8, 2018
Pharm Company: * KYOWA KIRIN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Poteligeo Overview

Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[1] The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease.[2] It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refracto...

Read more Poteligeo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Mogamulizumab

Recent Poteligeo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Poteligeo: (1 result)

Sorted by National Drug Code

• 42747-761 Poteligeo 4 mg/ml Intravenous Injection by Kyowa Kirin, Inc.

Other drugs which contain Mogamulizumab-kpkc or a similar ingredient: (1 result)

• MOGAMULIZUMAB